Open Congress : Blog Articles for H.R.5629 Pathway for Biosimilars Act2010-06-27T20:00:00Zopencongress.orgtag:opencongress.org,2007:/bill/blog/49688H.R.5629: Oil Spill Accountability and Environmental Protection ...tag:opencongress.org,2010-06-27:/commentary/104821572010-06-27T20:00:00Zopencongress.org
The same bill has been introduced in the United States Senate by Senator Charles Schumer (D-NY), and a competing bill, the “Pathways for Biosimilars Act” (HR 5629), has been introduced in the House by Representative Anna Eshoo (D-CA). ... Source: Rocck<br /><br /><a href="http://www.opencongress.org/bill/111-h5629/show">Go to article</a> Patent Docs: Top Stories of 2008: #9 to #6tag:opencongress.org,2009-01-03:/commentary/39188412009-01-03T19:00:00ZPatent Docs
Five follow-on biologics bills were introduced during the 110th Congress: H.R. 1956 (which provides twelve years of data exclusivity and two years of market exclusivity), S. 1695 and H.R. 5629 (which provide four years of data ...<br /><br /><a href="http://www.patentdocs.org/2009/01/top-stories-of-2008-9-to-6.html">Go to article</a> Patent Docs: Teva CEO Predicts Passage of Follow-on Biologics Bill ...tag:opencongress.org,2009-01-01:/commentary/38983472009-01-01T19:00:00ZPatent Docs
We also reported last summer that the Biotechnology Industry Organization (BIO) indicated that either H.R. 1956 (providing fourteen years of exclusivity), H.R. 5629 (providing twelve years of exclusivity), or S. 1695 (also providing ...<br /><br /><a href="http://www.patentdocs.org/2009/01/teva-ceo-predicts-passage-of-followon-biologics-bill-in-2009.html">Go to article</a> GoozNews: Biosimilars, Biogenerics Not the Sametag:opencongress.org,2008-12-13:/commentary/36991292008-12-13T19:00:00ZGoozNews
Anna Eshoo’s H.R.5629 each call for testing drugs for safety, purity and “potency.â€* The FDA uses potency as a synonym for efficacy. In other words, all three bills would mandate clinical trial effectiveness testing – the expensive ...<br /><br /><a href="http://www.gooznews.com/archives/001272.html">Go to article</a> More biopharmas lobby on biogenerics - FierceBiotechtag:opencongress.org,2008-12-09:/commentary/36556242008-12-09T19:00:00ZFierceBiotech -
Jay Inslee (D, WA) as well as H.R. 5629, the Pathway for Biosimilars Act, introduced by Reps. Anna Eshoo (D, CA) and Joe Barton (R, TX). BIO supports a pathway which protects patient safety and provides incentives for continued ...<br /><br /><a href="http://www.fiercebiotech.com/story/more-biopharmas-lobby-biogenerics/2008-12-09?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0">Go to article</a> Economist Argues That 7 Years Ought to be Enough for Biologic Data ...tag:opencongress.org,2008-11-19:/commentary/36991302008-11-19T19:00:00ZBio Pharma Bonanza
HR 5629, sponsored by Representatives Eshoo and Barton, would guarantee 12 years of data exclusivity, with an additional two years for a new indication and six months for pediatric exclusivity. In contrast, recent legislation introduced ...<br /><br /><a href="http://www.biopharmabonanza.com/bio-pharma-bonanza/economist-argues-that-7-years-ought-to-be-enough-for-biologic-data-exclusivity/">Go to article</a> Patent Baristas » Economist Argues That 7 Years Ought to be Enough ...tag:opencongress.org,2008-11-19:/commentary/35203612008-11-19T19:00:00ZPatent Baristas
H.R. 5629, sponsored by Representatives Eshoo and Barton, would guarantee 12 years of data exclusivity, with an additional two years for a new indication and six months for pediatric exclusivity. In contrast, recent legislation ...<br /><br /><a href="http://patentbaristas.com/archives/2008/11/20/economist-argues-that-7-years-ought-to-be-enough-for-biologic-data-exclusivity/">Go to article</a> Economist Argues That 7 Years Ought to be Enough for Biologic Data ...tag:opencongress.org,2008-11-19:/commentary/33899252008-11-19T19:00:00ZPharmaReports.net
H.R. 5629, sponsored by Representatives Eshoo and Barton, would guarantee 12 years of data exclusivity, with an additional two years for a new indication and six months for pediatric exclusivity. In contrast, recent legislation ...<br /><br /><a href="http://www.farmanux.com/wpnews/2008/11/economist-argues-that-7-years-ought-to-be-enough-for-biologic-data-exclusivity/">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-11-09:/commentary/37347442008-11-09T19:00:00ZPharmaceutical Technology Magazine
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=552658">Go to article</a> UAEM Calls on AAU to Withdraw Endorsement of Eshoo-Barton Follow ...tag:opencongress.org,2008-10-14:/commentary/30501512008-10-14T20:00:00ZUniversities Allied for Essential Medicines
Universities Allied for Essential Medicines (UAEM) today called on Robert M. Berdahl, President of the Association of American Universities (AAU), to withdraw its recent endorsement of HR 5629, the “Pathway for Biosimilars Acts,â€* which ...<br /><br /><a href="http://www.essentialmedicine.org/uaem-calls-on-aau/">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-10-09:/commentary/36404352008-10-09T20:00:00ZPharmaceutical Technology - Manufacturing
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/News/article/detail/552658">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-09-24:/commentary/39047252008-09-24T20:00:00ZPharmaceutical Technology Magazine
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/Manufacturing/Study-Promotes-HatchndashWaxman-Model-for-Biologic/ArticleStandard/Article/detail/552658?contextCategoryId=35097&ref=25">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-09-24:/commentary/38036112008-09-24T20:00:00ZPharmaceutical Technology - Manufacturing
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/Manufacturing/Study-Promotes-HatchndashWaxman-Model-for-Biologic/ArticleStandard/Article/detail/552658">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-09-24:/commentary/36120422008-09-24T20:00:00ZPharmaceutical Technology Magazine
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/Manufacturing/Study-Promotes-HatchndashWaxman-Model-for-Biologic/ArticleStandard/Article/detail/552658?contextCategoryId=35097">Go to article</a> Study Promotes Hatch–Waxman Model for Biologics Exclusivity ...tag:opencongress.org,2008-09-24:/commentary/33587502008-09-24T20:00:00ZPharmaceutical Technology Magazine
... Act (HR 5629), introduced by Representative Anna Eshoo (D-CA) and Representative Joseph Barton (R-TX); The Patient Protection and Innovative Biologic Medicines Act of 2007 (HR1956), introduced by Representative Jay Inslee (D-WA). ...<br /><br /><a href="http://pharmtech.findpharma.com/pharmtech/Manufacturing/Study-Promotes-HatchndashWaxman-Model-for-Biologic/ArticleStandard/Article/detail/552658?ref=25">Go to article</a> CQ Politics | Report: Increased Competition Will Produce Better ...tag:opencongress.org,2008-09-24:/commentary/33587492008-09-24T20:00:00ZTop Stories from CQ
Anna G. Eshoo , D-Calif., introduced a measure ( HR 5629 ) that would allow for a period of data exclusivity of 14 years between innovator companies — firms that are developing new biologic drugs — and firms producing follow-on biologic ...<br /><br /><a href="http://www.cqpolitics.com/wmspage.cfm?docID=hbnews-000002953529">Go to article</a> Red or Blue: We’ll Likely to See Biosimilars Either Waytag:opencongress.org,2008-09-23:/commentary/28847762008-09-23T20:00:00ZBio Pharma Bonanza
See also HR 5629: Pathway for Biosimilars Act. The legislation includes standards for the FDA to approve follow-on biologics as well as a period of exclusivity for the brand name drug company. The Act amends section 351 of the Public ...<br /><br /><a href="http://www.biopharmabonanza.com/bio-pharma-bonanza/red-or-blue-we%E2%80%99ll-likely-to-see-biosimilars-either-way/">Go to article</a> Waxman: FOBs Would Ensure Market Competitiontag:opencongress.org,2008-09-21:/commentary/31334102008-09-21T20:00:00ZHTA Blog
Specifically, BIO has said it supports HR 5629, introduced into the House by Reps. Anna Eshoo (D-Calif.) and Joe Barton (R-Texas), which calls for up to 14.5 years of exclusivity for innovators; HR 1956, introduced by Jay Inslee (D-Wash ...<br /><br /><a href="http://www.htablog.com/2008/09/waxman-fobs-would-ensure-market.html">Go to article</a> CQ Politics | Less Is Better On Biologic Exclusivity, Candidates ...tag:opencongress.org,2008-09-18:/commentary/35985892008-09-18T20:00:00ZTop Stories from CQ
Anna G. Eshoo , D-Calif., introduced a measure ( HR 5629 ) that would allow for a period of data exclusivity of 14 years, and is supported by the biotech industry. The Senate Health, Education, Labor and Pensions Committee has approved ...<br /><br /><a href="http://www.cqpolitics.com/wmspage.cfm?docID=hbnews-000002955003">Go to article</a> The Pathway for Biosimilars Act - Path or Detour?tag:opencongress.org,2008-09-18:/commentary/28670382008-09-18T20:00:00ZAll Articles on Martindale.com
With the introduction of the bipartisan Pathway for Biosimilars Act, HR 5629 introduced by Congresswoman Anna Eshoo (D-CA) and committee ranking member Joe Barton (R-TX), many questions have arisen as to whether this proposed ...<br /><br /><a href="http://www.martindale.com/biotech-life-sciences/article_McGuireWoods-LLP_510318.htm">Go to article</a> Resolution Trust Corporation and Congresstag:opencongress.org,2008-09-16:/commentary/33899272008-09-16T20:00:00ZDocstoc feed for: BUZZ
H.R. 5629. Resolution Trust Corporation Asset Recovery Act of 1992. 102d Cong., 2d sess., July 21, 1992. U.S. Senate. S. 2155. Resolution Trust Corporation Reorganization Act. 101st Cong., 2d sess., February 21, 1990. ———. S. 3112. ...<br /><br /><a href="http://www.docstoc.com/docs/1481232/Resolution-Trust-Corporation-and-Congress">Go to article</a> Report: Increased Competition Will Produce Better, Cheaper Follow ...tag:opencongress.org,2008-09-16:/commentary/33083882008-09-16T20:00:00ZNude Anna Biella
biologic drugs but none of those bills are expected to pass before Congress adjourns for the year. Rep. Anna G. Eshoo , D-Calif., introduced a measure (HR 5629) that would allow for a period of data exclusivity of 14 years between ...<br /><br /><a href="http://nd.hotnudeblogs.com/blogs/nude-Anna-Biella/343478/report-increased-competition-will/">Go to article</a> follow-on biologics (fobs)tag:opencongress.org,2008-09-03:/commentary/31334092008-09-03T20:00:00Zhealthpoint PA
two pieces of federal legislation involving fobs:. hr 1956 - inslee - “patient protection & innovative biologic medicines act of 2007″. hr 5629 - eshoo/barton - “pathway for biosimilars actâ€*<br /><br /><a href="http://www.healthpointpa.com/archives/follow-on-biologics-fobs/">Go to article</a> Virginia Biotechnology Associationtag:opencongress.org,2008-08-06:/commentary/33587522008-08-06T20:00:00ZVirginia Biotechnology Association
Jay Inslee (D-WA) “The Patient Protection and Innovative Biologic Medicines Act of 2007,â€* and H.R. 5629, sponsored by Reps. Anna Eshoo (D-CA) and Joe Barton (R-TX), “The Pathway for Biosimilars Act of 2008.â€* According to BIO, both of ..<br /><br /><a href="http://www.vabio.org/insmed-continues-fight-for-generic-biologic-approval/">Go to article</a> medworm query: cialis online (50 Ñ*ообщений)tag:opencongress.org,2008-06-27:/commentary/31334122008-06-27T20:00:00Zcialis blog news
one bill (hr 5629) by rep. anna eshoo (d-calif.) would allow for a 14-year period of data exclusivity, while another bill (hr 1038) by rep. henry waxman (d-calif.) contains no exclusivity period (mccarthy, cq healthbeat, 6/26). ...<br /><br /><a href="http://cialisblognews.blogspot.com/2008/06/medworm-query-cialis-online-50_28.html">Go to article</a> CBO Savings Estimate for Follow-On Biologics, Biotechnology ...tag:opencongress.org,2008-06-26:/commentary/38289032008-06-26T20:00:00ZThomasNet Industrial Newsroom -
H.R. 1956, the Patient Protection and Innovative Biologic Medicines Act of 2007; H.R. 5629, the Pathway for Biosimilars Act; and S. 1695 all come close to striking this necessary balance. "Notably, the CBO study projects savings in-line ...<br /><br /><a href="http://news.thomasnet.com/companystory/546186">Go to article</a> Biogenerics Would Save How Much?tag:opencongress.org,2008-06-25:/commentary/23993162008-06-25T20:00:00ZPharmalot
The bills, by the way, are S. 1695, the Biologics Price Competition and Innovation Act of 2007; HR 1956, the Patient Protection and Innovative Biologic Medicines Act of 2007; and HR 5629, the Pathway for Biosimilars Act. If you go to ...<br /><br /><a href="http://www.pharmalot.com/2008/06/biogenerics-would-save-how-much/">Go to article</a> House Commerce Committee Posts Responses to its Questions on ...tag:opencongress.org,2008-06-18:/commentary/32820882008-06-18T20:00:00ZFDA Law Blog
Anna Eshoo (D-CA), who is a member of the Subcommittee on Health, introduced the Pathway for Biosimilars Act (HR 5629). In February 2007, Rep. Henry Waxman (D-CA), who is also a member of the subcommittee, introduced the Access to ...<br /><br /><a href="http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2008/06/house-commerce.html">Go to article</a> [IHRO] Ariyan Invasion; The Indus Valley Decipherment Hoax ...tag:opencongress.org,2008-06-14:/commentary/24385292008-06-14T20:00:00ZHuman Rights Movements
1 ((sup)*(/sup), HR 5629, ASI 63.10.371, HU 441; photographed by Erja Lahdenper. Courtesy ASI, Government of India. H-103a, Vol. 1 (*), 2789, ASI 63.11.116, HU 601; photographed by Erja Lahdenper. Courtesy ASI, Government of India. ...<br /><br /><a href="http://humanrightsmovement.blogspot.com/2008/06/ihro-ariyan-invasion-indus-valley.html">Go to article</a> Letter: Data Exclusivity a Necessity for Creation of New Biologicstag:opencongress.org,2008-06-10:/commentary/23412372008-06-10T20:00:00ZCQ healthbeat News
Anna G. Eshoo, D-Calif., and Joe L. Barton, R-Texas, in support of the lawmakers’ legislation that would create an approval pathway for follow-on biologics (HR 5629). The letter highlights the bill’s proposed data exclusivity period as ...<br /><br /><a href="http://public.cq.com/docs/hb/hbnews110-000002894843.html">Go to article</a> WALSH CO-SPONSORS BILL TO PROTECT CONSUMERS AND FACILITATE ...tag:opencongress.org,2008-06-09:/commentary/36556252008-06-09T20:00:00ZPress Releases
(Washington D.C.)- Congressman Jim Walsh today announced that he has co-sponsored legislation -- H.R. 5629, the Pathway for Biosimilars Act -- to hold biosimilars to the same Food and Drug Administration (FDA) approval standards as the ...<br /><br /><a href="http://walsh.house.gov/list/press/ny25_walsh/pr_080604.html">Go to article</a> FDALegislativeWatch: Most Biosimilars Would Need Clinical Trials ...tag:opencongress.org,2008-06-08:/commentary/33587512008-06-08T20:00:00ZFDALegislativeWatch
In a letter to Eshoo and Barton, Biotechnology Industry Organization CEO Jim Greenwood endorses their bill, H.R. 5629, because it "recognizes the need for clinical trial evidence and data, including immunogenicity testing, ...<br /><br /><a href="http://www.fdalegislativewatch.com/2008/06/most-biosimilar.html">Go to article</a> WALSH CO-SPONSORS BILL TO PROTECT CONSUMERS AND FACILITATE ...tag:opencongress.org,2008-06-03:/commentary/22705862008-06-03T20:00:00ZPress Releases
(Washington DC)- Congressman Jim Walsh today announced that he has co-sponsored legislation -- HR 5629, the Pathway for Biosimilars Act -- to hold biosimilars to the same Food and Drug Administration (FDA) approval standards as the ...<br /><br /><a href="http://www.house.gov/apps/list/press/ny25_walsh/pr_080604.html">Go to article</a> The Latest from Orange Book Blogtag:opencongress.org,2008-05-21:/commentary/24826162008-05-21T20:00:00Zallaboutviagraonline
Patent Litigation Under a Future Biosimilars Act. Posted: 21 May 2008 08:17 PM CDT. Biopharmaceuticals, such as Epogen® (epoetin) and Erbitux® (cetuximab), are becoming increasingly important for the treatment of disease. ...<br /><br /><a href="http://allaboutviagraonline-pro.blogspot.com/2008/05/latest-from-orange-book-blog_22.html">Go to article</a> Patent Litigation Under a Future Biosimilars Acttag:opencongress.org,2008-05-20:/commentary/31334112008-05-20T20:00:00ZOrange Book Blog
Anna Eshoo introduced the Pathway for Biosimilars Act (HR 5629). Compared to the Waxman and Kennedy bills, the Eshoo bill would establish a relatively simple scheme for exchanging patent information and conducting patent litigation. ...<br /><br /><a href="http://www.orangebookblog.com/2008/05/patent-litigation-under-a-future-biosimilars-act.html">Go to article</a> Health News from Medical News Today (60 Ñ*ообщений)tag:opencongress.org,2008-05-19:/commentary/24290962008-05-19T20:00:00ZMedici
HSE Warns Employers To Assess Risks Properly After Worker Loses Finger In Unguarded Circular Saw, UK Employers are being warned, by the Health and Safety Executive (HSE), to ensure they assess workplace machinery risks properly to ...<br /><br /><a href="http://medic-art.blogspot.com/2008/05/health-news-from-medical-news-today-60_20.html">Go to article</a> Industry Group Letter Indicates Qualified Support For Bill To ...tag:opencongress.org,2008-05-19:/commentary/22195112008-05-19T20:00:00ZMen's & Drug's
The Biotechnology Industry Organization has issued a letter to Reps. Anna Eshoo (D-Calif.) and Joe Barton (R-Texas) to indicate qualified support for a bill (HR 5629) that they have introduced to allow FDA to approve generic biotech ...<br /><br /><a href="http://blog.find-group.com/?p=2159">Go to article</a> industry group letter indicates qualified aupport for bill to ...tag:opencongress.org,2008-05-18:/commentary/31334132008-05-18T20:00:00ZMedical News
anna eshoo (d-calif.) and joe barton (r-texas) to indicate qualified support for a bill (hr 5629) that they have introduced to allow fda to approve generic biotech medications, cq healthbeat reports (mccarthy, cq healthbeat, 5/16).<br /><br /><a href="http://www.news-medical.net/?id=38462">Go to article</a> coalition releases letter in support of follow-on biologicstag:opencongress.org,2008-04-10:/commentary/31334142008-04-10T20:00:00ZMedical,Health News and Articles
bio has drafted its own letter supporting a follow-on biologics bill (hr 5629) proposed by rep. anna eshoo (d-calif.) and house energy and commerce ranking member joe barton (r-texas). according to bio’s draft letter, the legislation’s ...<br /><br /><a href="http://03530.com/2008/04/12/coalition-releases-letter-in-support-of-follow-on-biologics.html">Go to article</a> Coalition Releases Letter In Support Of Follow-On Biologicstag:opencongress.org,2008-04-10:/commentary/20405302008-04-10T20:00:00ZMen's & Drug's
BIO has drafted its own letter supporting a follow-on biologics bill (HR 5629) proposed by Rep. Anna Eshoo (D-Calif.) and House Energy and Commerce ranking member Joe Barton (R-Texas). According to BIO’s draft letter, the legislation’s ...<br /><br /><a href="http://blog.find-group.com/?p=859">Go to article</a> Proposed Bill Could Pave the Way for the Approval of Biogenericstag:opencongress.org,2008-04-06:/commentary/20327182008-04-06T20:00:00ZFrost.com - Pharmaceuticals and Biotechnology...
HR 5629 is a bipartisan bill called the Pathways for Biosimilars Act. This bill was introduced by Representatives Anna Eshoo (Democrat, California) and Joe Barton (Republican, Texas). This bill provides a way for biosimilars to be ...<br /><br /><a href="http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=127102252">Go to article</a> FDALegislativeWatch: Potential Federal Drug Savings Could Propel ...tag:opencongress.org,2008-04-02:/commentary/37645052008-04-02T20:00:00ZFDALegislativeWatch
Schmickel compared H.R. 5629 to S. 1695, approved last year by the HELP panel, and the administration position enunciated by HHS Secretary Michael Leavitt in a letter to that committee, and acknowledged that some challenging issues ...<br /><br /><a href="http://www.fdalegislativewatch.com/2008/04/potential-feder.html">Go to article</a> Patent Docstag:opencongress.org,2008-03-18:/commentary/17594582008-03-18T20:00:00ZAntibody Technologies
The bill (HR 5629), which would amend Section 351 of the Public Health Service Act to create a regulatory pathway for biosimilars, has been referred to the Committee on Energy. ...<br /><br /><a href="http://antibody-technologies-biotechnology.blogspot.com/2008/03/patent-docs_19.html">Go to article</a> New Follow-on Biologics Bill Introduced in the Housetag:opencongress.org,2008-03-17:/commentary/17594562008-03-17T20:00:00ZPatent Docs
... at right) introduced a new biologics bill in the House. The bill (HR 5629), which would amend Section 351 of the Public Health Service Act to create a regulatory pathway for biosimilars, has been referred to the Committee on Energy...<br /><br /><a href="http://www.patentdocs.net/patent_docs/2008/03/new-follow-on-b.html">Go to article</a> GPhA opposes HR 5629, biologics billtag:opencongress.org,2008-03-16:/commentary/37645042008-03-16T20:00:00ZModern Medicine - Clinical Pharmacology
Generic Pharmaceutical Association issues statement on HR 5629 biologics bill.<br /><br /><a href="http://www.modernmedicine.com/modernmedicine/Modern+Medicine+News/GPhA-opposes-HR-5629-biologics-bill/ArticleStandard/Article/detail/503694?contextCategoryId=40153&ref=25">Go to article</a> GPhA opposes HR 5629, biologics billtag:opencongress.org,2008-03-16:/commentary/17934212008-03-16T20:00:00ZDrug Topics - Drug Topics Daily News
Generic Pharmaceutical Association issues statement on HR 5629 biologics bill.<br /><br /><a href="http://drugtopics.modernmedicine.com/drugtopics/Modern+Medicine+News/GPhA-opposes-HR-5629-biologics-bill/ArticleStandard/Article/detail/503694?contextCategoryId=10239&ref=25">Go to article</a> Rep. Eshoo Formally Introduces “Pathway for Biosimilars Act ...tag:opencongress.org,2008-03-15:/commentary/17406022008-03-15T20:00:00ZFDA Law Blog
Last Friday, Representatives Anna Eshoo (D-CA) and Joe Barton (R-TX) announced the introduction of HR 5629, the “Pathway for Biosimilars Act.â€* We previously reported on a draft version of the bill circulated on Capitol Hill in February ...<br /><br /><a href="http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2008/03/rep-eshoo-forma.html">Go to article</a> H.R.5629: Pathway for Biosimilars Act - U.S. ... - OpenCongresstag:opencongress.org,2008-03-12:/commentary/143688342008-03-12T01:00:00Zopencongress.org
H.R.5629 - Pathway for Biosimilars Act. To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2). Close ...<br /><br /><a href="/url?q=http://www.opencongress.org/bill/110-h5629/show&sa=U&ei=BnKGT_7qBMjB8AHgnJXDCA&ved=0CCUQmAEwAA&usg=AFQjCNGyEjFjLfq_9VAyBYqTfR56p-UkGA">Go to article</a> H.R.5629: Pathway for Biosimilars Act - U.S. ... - OpenCongresstag:opencongress.org,2008-03-12:/commentary/143472072008-03-12T01:00:00Zopencongress.org
H.R.5629 - Pathway for Biosimilars Act. To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2). Close ...<br /><br /><a href="/url?q=http://www.opencongress.org/bill/110-h5629/show&sa=U&ei=bMiFT425O6Oc2AWA9omHCQ&ved=0CCUQmAEwAA&usg=AFQjCNFlWHpyDjLoOYNjLy4brLFtzUy27g">Go to article</a> H.R.5629: Pathway for Biosimilars Act - U.S. ... - OpenCongresstag:opencongress.org,2008-03-12:/commentary/143300532008-03-12T01:00:00Zopencongress.org
H.R.5629 - Pathway for Biosimilars Act. To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2). Close ...<br /><br /><a href="/url?q=http://www.opencongress.org/bill/110-h5629/show&sa=U&ei=9B2FT7y3L8jw2gX31L2GCQ&ved=0CCUQmAEwAA&usg=AFQjCNGqrGb9V3f3PP4LBcFMH2NahJGkGA">Go to article</a> H.R.5629: Pathway for Biosimilars Act - U.S. ... - OpenCongresstag:opencongress.org,2008-03-12:/commentary/143087652008-03-12T01:00:00Zopencongress.org
H.R.5629 - Pathway for Biosimilars Act. To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2). Close ...<br /><br /><a href="/url?q=http://www.opencongress.org/bill/110-h5629/show&sa=U&ei=j3iET8yCK4eq2QWFhe2WCQ&ved=0CCUQmAEwAA&usg=AFQjCNFFuIKFKiQXlL31U-SUD1Us1CassQ">Go to article</a> H.R.5629: Pathway for Biosimilars Act - U.S. ... - OpenCongresstag:opencongress.org,2008-03-12:/commentary/142925272008-03-12T01:00:00Zopencongress.org
H.R.5629 - Pathway for Biosimilars Act. To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2). Close ...<br /><br /><a href="/url?q=http://www.opencongress.org/bill/110-h5629/show&sa=U&ei=uc2DT-mSB4ag2QXv3ajuCA&ved=0CCUQmAEwAA&usg=AFQjCNEcs0ddHkOD3bnmlmE0WxyXn3PPuQ">Go to article</a>